Company Description
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States.
The company’s lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
It also developing VG-3927, an orally available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial.
It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2.
Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2020 |
| IPO Date | Jan 7, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Ivana Magovcevic-Liebisch |
Contact Details
Address: 100 Forge Road, Suite 700 Watertown, Massachusetts 02472 United States | |
| Phone | 857 254 4445 |
| Website | vigilneuro.com |
Stock Details
| Ticker Symbol | VIGL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001827087 |
| CUSIP Number | 92673K108 |
| ISIN Number | US92673K1088 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. | President, Chief Executive Officer and Director |
| Jennifer Ziolkowski CPA | Chief Financial Officer |
| Dr. Petra Kaufmann M.D., M.S. | Chief Medical Officer |
| Sharon Morani | Senior Director of Facilities and Operations |
| Dr. David Gray Ph.D. | Chief Scientific Officer |
| Eric Brophy | Senior Manager of Information Technology |
| Leah Gibson | Vice President of Investor Relations and Corporate Communications |
| April Effort M.B.A., M.S. | Vice President and Head of Corporate Development |
| Heidi Mizenko M.B.A. | Senior Human Resources Associate |
| Evan A. Thackaberry DABT, Ph.D. | Senior Vice President and Head of Early Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 5, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 5, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 5, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 5, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 5, 2025 | POS AM | Post-Effective amendments for registration statement |
| Aug 5, 2025 | POS AM | Post-Effective amendments for registration statement |
| Aug 5, 2025 | 25-NSE | Filing |
| Aug 5, 2025 | 8-K | Current Report |
| Aug 5, 2025 | 10-Q | Quarterly Report |
| Jul 28, 2025 | 8-K | Current Report |